New Data on Zogenix’s ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting
November 22, 2016 16:05 ET
|
Zogenix, Inc.
Interim Results of Investigator Initiated Phase 2 study of ZX008 in Lennox Gastaut Syndrome to be PresentedUpdate from Ongoing Open-Label Prospective Study of ZX008 in Dravet Syndrome Will Also be...
Zogenix to Participate in Oppenheimer Life Sciences Summit 2016
November 22, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Participate in Stifel 2016 Healthcare Conference
November 08, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results
November 07, 2016 16:01 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Release Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 7
October 31, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Participate in Two Upcoming Investor Conferences
September 20, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to have Significant Presence at 12th European Congress on Epileptology
September 08, 2016 16:05 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
August 09, 2016 16:01 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9
August 02, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
June 21, 2016 08:00 ET
|
Zogenix, Inc.
- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc....